Insider Transactions in Q1 2021 at Blueprint Medicines Corp (BPMC)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 15
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,000
-0.37%
|
$106,000
$106.46 P/Share
|
|
Mar 15
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,000
+1.79%
|
$36,000
$36.05 P/Share
|
|
Mar 04
2021
|
Jeffrey W. Albers |
SELL
Open market or private sale
|
Direct |
18,986
-1.28%
|
$1,689,754
$89.65 P/Share
|
|
Mar 04
2021
|
Jeffrey W. Albers |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+4.96%
|
$80,000
$8.8 P/Share
|
|
Mar 04
2021
|
Christina Rossi CHIEF OPERATING OFFICER |
SELL
Open market or private sale
|
Direct |
1,359
-2.06%
|
$118,233
$87.86 P/Share
|
|
Mar 04
2021
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
SELL
Open market or private sale
|
Direct |
1,210
-3.02%
|
$105,270
$87.81 P/Share
|
|
Mar 04
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,893
-2.73%
|
$164,691
$87.81 P/Share
|
|
Mar 04
2021
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,507
-2.49%
|
$131,109
$87.8 P/Share
|
|
Mar 04
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
1,952
-1.75%
|
$169,824
$87.85 P/Share
|
|
Mar 04
2021
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
SELL
Open market or private sale
|
Direct |
1,693
-2.61%
|
$147,291
$87.79 P/Share
|
|
Mar 04
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
857
-3.4%
|
$74,559
$87.92 P/Share
|
|
Mar 03
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
515
-3.91%
|
$50,470
$98.45 P/Share
|
|
Mar 01
2021
|
Fouad Namouni PRESIDENT, R & D |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+22.28%
|
-
|
|
Mar 01
2021
|
L. Becker Hewes CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+29.94%
|
-
|
|
Mar 01
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
SELL
Open market or private sale
|
Direct |
1,700
-11.43%
|
$168,300
$99.51 P/Share
|
|
Mar 01
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,700
+5.37%
|
$8,500
$5.34 P/Share
|
|
Mar 01
2021
|
Ariel Hurley PRINCIPAL ACCOUNTING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
3,187
+19.48%
|
-
|
|
Mar 01
2021
|
Christopher K. Murray CHIEF TECHNICAL OPERATIONS |
BUY
Grant, award, or other acquisition
|
Direct |
6,250
+23.72%
|
-
|
|
Mar 01
2021
|
Debra Durso Bumpus CHIEF PEOPLE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+28.63%
|
-
|
|
Mar 01
2021
|
Michael Landsittel CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+30.05%
|
-
|
|
Mar 01
2021
|
Tracey L Mc Cain EVP AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+27.32%
|
-
|
|
Mar 01
2021
|
Jeffrey W. Albers |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+18.06%
|
-
|
|
Mar 01
2021
|
Christina Rossi CHIEF OPERATING OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+28.31%
|
-
|
|
Mar 01
2021
|
Kate Haviland CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
13,062
+18.94%
|
-
|
|
Feb 22
2021
|
Marion Dorsch Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,578
-33.2%
|
$757,800
$100.0 P/Share
|
|
Feb 22
2021
|
Marion Dorsch Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,578
+24.92%
|
$280,386
$37.11 P/Share
|
|
Jan 04
2021
|
George Demetri |
SELL
Open market or private sale
|
Direct |
758
-17.55%
|
$84,896
$112.15 P/Share
|